-
A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED MULTICENTER OUTPATIENT PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH EPILEPSY WITH A PREDICTABLE SEIZURE PATTERN.
Staccato alprazolam is being developed for the indication of rapid cessation of a prolonged focal or generalized seizure that has not progressed to status epilepticus ...Phase
Interventional
-
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence
EMBER-4 is a Phase 3 global, randomized, open-label study of adjuvant imlunestrant vs SOC adjuvant ET of physician’s choice in participants who have previously ...Phase
Interventional
-
Integrating financial coaching and smoking cessation coaching for people with low income who smoke: a randomized controlled trial
This study conduct a two-arm, parallel-group randomized controlled trial. We will recruit and randomize 900 smokers (n=450 per arm) to either: (1) Control: Standard ...Phase
Interventional
-
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease chronic kidney disease and systemic inflammation
ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammationPhase
Interventional
-
Randomized multicenter open-label phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-positive recurrent platinum-sensitive epithelial ovarian fallopian tube or primary peritoneal cancers who have not progressed after second line platinum-based chemotherapy plus bevacizumab(GOG 3078)
The purposes of this study are: • To determine if mirvetuximab soravtansine (MIRV) plus BEV is effective at managing subjects' type of cancer in a maintenance ...Phase
Interventional
-
A two-part randomized placebo controlled double blind multicenter Phase 3 study to evaluate the efficacy and safety of linerixibat for the treatment of cholestatic pruritus in participants with primary biliary cholangitis (PBC).
This study is a Phase 3, multicenter, 2-part (Part A and Part B), randomized, double-blind, placebo-controlled study in PBC patients with moderate to severe pruritus ...Phase
Non-Interventional
-
The effect of semaglutide in subjects with non-cirrhotic non-alcoholic steatohepatitis
This is a randomised, multicentre, double-blinded, parallel-group trial comparing semaglutide s.c. 2.4 mg once-weekly versus placebo in subjects with NASH and fibrosis stage ...Phase
Interventional
-
A randomized parallel-group double-blind placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo both in combination with a glucocorticoid taper regimen in patients with giant cell arteritis (GCA) (GCAptAIN)
The purpose of the study is to demonstrate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously in adult patients with ...Phase
Interventional
-
PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE WITH A NON RANDOMIZED SINGLE ARM US EXTENSION OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN PATIENTS WITH FOLLICULAR LYMPHOMA AFTER AT LEAST ONE LINE OF SYSTEMIC THERAPY
This is a Phase III, open-label, multicenter, randomized controlled trial in patients with R/R FL after receiving at least 1 line of systemic therapy ...Phase
Interventional
-
Site for A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Non-Biologic Lupus Standard of Care
Site for This is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study designed to evaluate the efficacy and safety of BIIB059 in participants = 18 years ...Phase
Interventional
